Suven Pharmaceuticals Limited is a bio-pharmaceutical company based in Hyderabad, India, with operations extending to the United States, Europe, and other international markets. Founded in 2018, the company focuses on the development, manufacturing, and sale of new chemical entity intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs. Suven Pharmaceuticals operates primarily through contract research and manufacturing services, catering to the needs of pharmaceutical, biotechnology, and chemical companies. As a subsidiary of Jasti Property and Equity Holdings Private Limited, the company strives to meet customer demands and expectations in the pharmaceutical industry.
NJ Bio, Inc. is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) that focuses on providing integrated chemistry and biology services to the biotech and pharmaceutical industries. The company specializes in a variety of offerings, including multistep organic synthesis, medicinal chemistry, bioconjugation, and antibody-drug conjugates. Additionally, NJ Bio provides services such as protein production, cell-based assays, and bioanalytical testing. By delivering these comprehensive solutions, the company aims to support clients in accelerating their product development and research initiatives.
Casper Pharma
Acquisition in 2024
Casper Pharma is a specialty pharmaceutical company dedicated to enhancing patients' lives by developing, acquiring, and commercializing pharmaceuticals. The company targets various medical needs across multiple therapeutic areas, including cardiovascular, gastrointestinal, urological, pain management, and ophthalmic markets. By leveraging its global network, Casper Pharma aims to provide innovative solutions that address unmet medical needs and improve healthcare outcomes for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.